

# Valentin Yurievich Skryabin

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4761783/valentin-yurievich-skryabin-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63

papers

5,400

citations

17

h-index

66

g-index

66

ext. papers

13,859

ext. citations

11.6

avg, IF

4.89

L-index

#	Paper	IF	Citations
63	Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The, 2020</i> , 396, 1204-1222	40	1847
62	Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The, 2020</i> , 396, 1223-1249	40	1013
61	Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. <i>Journal of the American College of Cardiology, 2020</i> , 76, 2982-3021	15.1	922
60	Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. <i>The Lancet Global Health, 2021</i> , 9, e144-e160	13.6	253
59	Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Neurology, The, 2021</i> , 20, 795-820	24.1	229
58	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950-2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The, 2020</i> , 396, 1160-1203	40	228
57	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The, 2020</i> , 396, 1135-1159	40	113
56	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The, 2020</i> , 396, 1250-1284	40	112
55	Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>Lancet, The, 2021</i> , 397, 2337-2360	40	97
54	Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.. <i>Lancet Public Health, The, 2022</i> ,	22.4	95
53	Hearing loss prevalence and years lived with disability, 1990-2019: findings from the Global Burden of Disease Study 2019. <i>Lancet, The, 2021</i> , 397, 996-1009	40	82
52	Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.. <i>JAMA Oncology, 2021</i> ,	13.4	51
51	Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. <i>Lancet, The, 2021</i> , 398, 870-905	40	43
50	Mapping subnational HIV mortality in six Latin American countries with incomplete vital registration systems. <i>BMC Medicine, 2021</i> , 19, 4	11.4	33
49	Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. <i>Lancet, The, 2020</i> , 396, 693-724	40	32
48	Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. <i>Lancet, The, 2021</i> , 398, 503-521	40	29
47	Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990-2050. <i>Lancet, The, 2021</i> , 398, 1317-1343	40	18

46	Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2019</b> , 97, 781-785	2.4	14
45	Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. <i>Drug Metabolism and Personalized Therapy</i> , <b>2017</b> , 32, 129-136	2	14
44	Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. <i>Human Psychopharmacology</i> , <b>2018</b> , 33, e2677	2.3	13
43	Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2018</b> , 11, 113-119	2.1	11
42	Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. <i>Lancet Public Health, The</i> , <b>2021</b> , 6, e482-e499	22.4	11
41	Public health utility of cause of death data: applying empirical algorithms to improve data quality. <i>BMC Medical Informatics and Decision Making</i> , <b>2021</b> , 21, 175	3.6	11
40	Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. <i>Nature Medicine</i> , <b>2021</b> , 27, 1761-1782	50.5	10
39	Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study. <i>Lancet HIV,the</i> , <b>2021</b> , 8, e363-e375	7.8	10
38	Pharmacogenetics of alcohol addiction: current perspectives. <i>The Application of Clinical Genetics</i> , <b>2019</b> , 12, 131-140	3.1	9
37	Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. <i>Lancet HIV,the</i> , <b>2021</b> , 8, e633-e651	7.8	9
36	Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. <i>Pharmacogenomics and Personalized Medicine</i> , <b>2017</b> , 10, 209-215	2.1	8
35	Global, regional, and national mortality among young people aged 10-24 years, 1950-2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , <b>2021</b> , 398, 1593-1618	40	8
34	Hallucinogen persisting perception disorder: A literature review and three case reports. <i>Journal of Addictive Diseases</i> , <b>2018</b> , 37, 268-278	1.7	7
33	How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?. <i>Drug Metabolism and Personalized Therapy</i> , <b>2020</b> , 35,	2	6
32	Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder. <i>Gene</i> , <b>2020</b> , 739, 144513	3.8	6
31	Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019. <i>Lancet Infectious Diseases, The</i> , <b>2021</b> ,	25.5	6
30	Effects of CYP2C19*17 Genetic Polymorphisms on the Steady-State Concentration of Diazepam in Patients With Alcohol Withdrawal Syndrome. <i>Hospital Pharmacy</i> , <b>2021</b> , 56, 592-596	1.1	5
29	Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000-2018. <i>Nature Human Behaviour</i> , <b>2021</b> , 5, 1027-1045	12.8	5

28	Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. <i>Drug Metabolism and Personalized Therapy</i> , <b>2018</b> , 33, 187-194	2	5
27	Chemsex in Moscow: investigation of the phenomenon in a cohort of men who have sex with men hospitalized due to addictive disorders. <i>International Journal of STD and AIDS</i> , <b>2020</b> , 31, 136-141	1.4	4
26	Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019.. <i>Lancet Diabetes and Endocrinology</i> , <b>2022</b> ,	18.1	4
25	The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Oncology</i> , <b>2021</b> ,	21.7	4
24	Emotional dysregulation features and problem gambling in university students: a pilot study. <i>Journal of Addictive Diseases</i> , <b>2020</b> , 38, 550-566	1.7	4
23	Effects of polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 111-123	2.6	3
22	Changes in sexual behavior patterns due to stimulants use: three case reports. <i>Journal of Addictive Diseases</i> , <b>2020</b> , 38, 375-379	1.7	2
21	Psychotic Disorders in Patients Who Use Synthetic Cannabinoids. <i>Journal of Psychiatric Practice</i> , <b>2019</b> , 25, 485-490	1.3	2
20	Clinical characteristics of synthetic cannabinoid-induced psychotic disorders: a single-center analysis of hospitalized patients. <i>Journal of Addictive Diseases</i> , <b>2018</b> , 37, 135-141	1.7	2
19	Analysing : an attempt to establish diagnosis for a film icon. <i>BJPsych Bulletin</i> , <b>2021</b> , 45, 329-332	1.2	2
18	CYP3A subfamily activity affects the equilibrium concentration of Phenazepam in patients with anxiety disorders and comorbid alcohol use disorder. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 449-457	2.6	1
17	An addiction to seeking fortune-telling services: a case report. <i>Journal of Addictive Diseases</i> , <b>2020</b> , 38, 223-228	1.7	1
16	Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders. <i>Drug Metabolism and Personalized Therapy</i> , <b>2020</b> , 35,	2	1
15	Edvard Munch: the collision of art and mental disorder. <i>Mental Health, Religion and Culture</i> , <b>2020</b> , 23, 570-578	1.1	1
14	Cybersex addiction in a gay man: a case report. <i>Journal of Addictive Diseases</i> , <b>2021</b> , 39, 425-431	1.7	1
13	Using the CYP3A Activity Evaluation to Predict the Efficacy and Safety of Diazepam in Patients With Alcohol Withdrawal Syndrome. <i>Journal of Pharmacy Practice</i> , <b>2021</b> , 897190021997000	1.3	1
12	and impact efficacy and safety of diazepam in patients with alcohol withdrawal syndrome.. <i>Nordic Journal of Psychiatry</i> , <b>2022</b> , 1-4	2.3	1
11	Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: the results of a randomized comparative study. <i>Journal of Addictive Diseases</i> , <b>2021</b> , 39, 513-525	1.7	0

10	Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder. <i>Pharmacogenomics Journal</i> , <b>2021</b> , 21, 435-439	3.5	o
9	Use of multidimensional item response theory methods for dementia prevalence prediction: an example using the Health and Retirement Survey and the Aging, Demographics, and Memory Study. <i>BMC Medical Informatics and Decision Making</i> , <b>2021</b> , 21, 241	3.6	o
8	The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome. <i>Bulletin of Siberian Medicine</i> , <b>2020</b> , 18, 119-126	0.4	
7	Assessment of the impact of the steady state level of microRNA hsa-miR-370-3p concentration on the efficacy and safety profile of fluvoxamine in patients with depressive disorders disorder comorbid with alcohol use disorders. <i>Vestnik Nevrologii, Psihatrii I Nejrohirurgii</i> , <b>2020</b> , 37-46	0.1	
6	Personalized approach to the administration of haloperidol in patients with acute alcoholic hallucinatie (literature review). <i>Vestnik Nevrologii, Psihatrii I Nejrohirurgii</i> , <b>2021</b> , 628-638	0.1	
5	Non-medical Use of Naphazoline (Naphthyzin): Two Case Reports. <i>Journal of Addiction Medicine</i> , <b>2020</b> , 14, e267-e270	3.8	
4	Relations of CYP2C19*2 genetic polymorphisms to plasma and saliva concentrations of diazepam in patients hospitalized for alcohol withdrawal. <i>Personalized Psychiatry and Neurology</i> , <b>2021</b> , 1, 84-92		
3	A case of olanzapine-associated rhabdomyolysis. <i>BJPsych Open</i> , <b>2021</b> , 7, S53-S53	5	
2	Polymorphism 3435c> t of the ABCB1 gene (rs1045642) does not affect the mirtazapine efficiency and safety profile in patients with depressive disorders comorbid with alcohol use disorder. <i>Bulletin of Siberian Medicine</i> , <b>2021</b> , 19, 73-79	0.4	
1	Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders. <i>Journal of Psychiatric Practice</i> , <b>2021</b> , 27, 372-379	1.3	